Topical ONYX-015 in the treatment of premalignant oral dysplasia: Another role for the cold virus?

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4476-4478

  Ganly, Ian ^a   Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CISPLATIN; FLUOROURACIL; ISOTRETINOIN; ONYX 015; VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HUMAN; LASER SURGERY; MOUTH CANCER; MOUTH HYGIENE; ONCOLYTIC VIROTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; XERODERMA; ADENOVIRUS; MOUTH TUMOR; NOTE; PRECANCER; TOPICAL DRUG ADMINISTRATION;

ADENOVIRIDAE; ADMINISTRATION, TOPICAL; HUMANS; MOUTH NEOPLASMS; MOUTHWASHES; PRECANCEROUS CONDITIONS; VIRAL VACCINES;

EID: 1542648391     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.997     Document Type: Editorial

References (30)

1. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376, 1996
2. Ganly I, Kirn D, Eckhardt G, et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6:798-806, 2000
3. Nemunaitis J, Ganly I, Khuri F, et al: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 60:6359-6366, 2000
4. Nemunaitis J, Khuri F, Ganly I, et al: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289-298, 2001
5. Khuri FR, Nemunaitis J, Ganly I, et al: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000
6. Rothmann T, Hengstermann A, Whitaker NJ, et al: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72:9470-9478, 1998
7. Hall AR, Dix BR, O'Carroll SJ, et al: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 4:1068-1072, 1998
8. Ridgway PJ, Hall AR, Myers CJ, et al: p53/E1b58kDa complex regulates adenovirus replication. Virology 237:404-413, 1997
9. McCormick F: ONYX-015 selectivity and the p14ARF pathway. Oncogene 19:6670-6672, 2000
10. Ries SJ, Brandts CH, Chung AS, et al: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6:1128-1133, 2000
11. Vasey PA, Shulman LN, Campos S, et al: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20:1562-1569, 2002
12. Makower D, Rozenblit A, Kaufman H, et al: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 9:693-702, 2003
13. Mulvihill S, Warren R, Venook A, et al: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 8:308-315, 2001
14. Reid T, Galanis E, Abbruzzese J, et al: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther 8:1618-1626, 2001
15. Sze DY, Freeman SM, Slonim SM, et al: Dr. Gary J. Becker Young Investigator Award: Intraarterial adenovirus for metastatic gastrointestinal cancer-Activity, radiographic response, and survival. J Vasc Interv Radiol 14:279-290, 2003
16. Rudin CM, Cohen EEW, Papadimitrakopoulou VA, et al: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21:4546-4552, 2003
17. Lee JJ, Hong WK, Hittelman WN, et al: Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6:1702-1710, 2000
18. Fan KF, Hopper C, Speight PM, et al: Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 78:1374-1383, 1996
19. Nauta JM, van Leengoed HL, Star WM, et al: Photodynamic therapy of oral cancer: A review of basic mechanisms and clinical applications. Eur J Oral Sci 104:69-81, 1996
20. Schoelch ML, Sekandari N, Regezi JA, et al: Laser management of oral leukoplakias: A follow-up study of 70 patients. Laryngoscope 109:949-953, 1999
21. Slaughter D, Southwick H, Smejkal W: Field cancerization in oral stratified squamous epithelium. Cancer 6:963-968, 1953
22. Hong WK, Endicott J, Itri LM, et al: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
23. Lippman SM, Shin DM, Lee JJ, et al: p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55:16-19, 1995
24. Papadimitrakopoulou VA, Hong WK, Lee JS, et al: Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up. J Natl Cancer Inst 89:257-258, 1997
25. Dimery IW, Hong WK, Lee JJ, et al: Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 8:85-89, 1997
26. Zhang L, Michelsen C, Cheng X, et al: Molecular analysis of oral lichen planus: A premalignant lesion? Am J Pathol 151:323-327, 1997
27. Murti PR, Warnakulasuriya KA, Johnson NW, et al: p53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 27:191-196, 1998
28. Shin DM, Kim J, Ro JY, et al: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321-326, 1994
29. Papadimitrakopoulou V, Izzo J, Lippman SM, et al: Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14:1799-1803, 1997
30. Sciubba JJ: Oral leukoplakia. Crit Rev Oral Biol Med 6:147-160, 1995